Open Access
Open access
Drugs and Drug Candidates, volume 3, issue 1, pages 126-147

Beta-Thalassemia: A Pharmacological Drug-Based Treatment

Shrabonti Biswas 1
Shanita Zaman Smrity 1
Md. Shimul Bhuia 1
Fatema Akter Sonia 1
Mst. Asma Aktar 1
Raihan Chowdhury 1
Tawhida Islam 1
Muhammad T. Islam 1
Gabriel Gonçalves Alencar 2
Cicera Laura Roque Paulo 2
Ana Pavla Almeida Diniz Gurgel 3
Henrique DM Coutinho 2
Show full list: 12 authors
1
 
Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
2
 
Laboratory of Microbiology and Molecular Biology, Department of Biological Chemistry, Regional University of Cariri, Crato 63105-000, Brazil
Publication typeJournal Article
Publication date2024-02-08
SJR
CiteScore
Impact factor
ISSN28132998
Abstract

This review was performed to determine the potential of drugs that can remove or decrease the requirements for blood transfusion among beta (β)-thalassemia patients. A comprehensive literature search was conducted to identify clinical trials and studies using PubMed Central, Google Scholar, PubMed, and ScienceDirect archived articles published from 1996 to November 2023. According to this review, clinical trials for a number of drugs, including luspatercept, sotatercept, mitapivat, etavopivat, hydroxyurea, rapamycin, decitabine, thalidomide, and quercetin, have been performed as part of efforts to improve the cure strategy for β-thalassemia. Of these drugs, luspatercept and sotatercept have exhibited particularly promising results and have been granted US Food and Drug Administration (FDA) approval for use in β-thalassemia patients. The mode of action for the drugs luspatercept and sotatercept involves the stimulation of hemoglobin (Hb) production or enhancement of its functionality, thereby decreasing reliance on blood transfusions and enhancing the overall quality of life. In this way, drugs like luspatercept and sotatercept present an opportunity to notably decrease the necessity for blood transfusions in β-thalassemia patients, improving their standard of living and overall prognosis. However, more research is needed to evaluate the effectiveness and safety of these drugs in the long run.

Found 

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Share
Cite this
GOST | RIS | BibTex | MLA
Found error?